A Randomized Study to Evaluate the Effect of an Inclisiran First Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 450 participants.

Also called NCT04929249

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 450 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04929249
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04929249. Randomized; no masking; primary purpose treatment. Start 2021-06-25 (actual); primary completion 2023-09-15 (actual). Results posted on 2024-09-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)
Acronym
V-INITIATE
Condition
Atherosclerotic Cardiovascular Disease
Intervention (Drug)
Inclisiran
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct04929249
Content hash
e35f93d3f613520a9a4e5edb9f5bcf4f41ebfd3a997e51313220841392273cba